Advanced Topics in Potent Compound Safety webinar series begins May 30th, 2013

Affygility Solutions is pleased to announce that its next Advanced Topics in Potent Compound Safety webinar series will begin on May 30th, 2013.

Potent Compound Safety Training From Your Own Office

potent-compound-safetyAvoid the hassle and expense of time-consuming travel. Attend this 5-module series from the convenience of your own office, or register your entire team and view in your own conference room (group discounts are available). Learn potent compound safety principles such as the definition of a potent compound, occupational exposure control banding, calculation of occupational exposure limits (OELs) for active pharmaceutical ingredients, engineering controls, and containment.

Each module is 2 hours long, with a 10-15 minute break at approximately the mid-point.

Register Early to Ensure a Spot

In order to ensure a high degree of interaction, Affygility Solutions limits the number of attendees for each module, so REGISTER EARLY. Register by May 1st, 2013 and receive 20% off each attendee by using the early discount code of “jh2mq7″ No other offers are discounts may be applied or combined.

Taught by Pharmaceutical Industry Experts

The Advanced Topics in Potent Compound Safety webinar series is taught by industry experts with advance degrees, professional certifications, and decades of pharmaceutical industry experience.

Share and Enjoy:
  • Print
  • email
  • PDF
  • Twitter
  • LinkedIn
  • Google Buzz
  • del.icio.us
  • Digg
  • Posterous
  • Reddit
  • StumbleUpon
  • Propeller
  • Technorati

About Dean Calhoun

Dean is the President and CEO of Affygility Solutions. Affygility Solutions provides environmental, health and safety software, potent compound safety, industrial hygiene, containment validation services to the pharmaceutical, biotechnology, and medical device industry. "Dean's Google+ Profile"
This entry was posted in control banding, potent compound safety, potent compound series. Bookmark the permalink.

Comments are closed.